Divya Bezwada

Divya Bezwada

Auto-generated profile, based on publicly available information

Divya Bezwada

Children’s Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2015 in Cancer Cell
Verified
Journal Article
Closed access
HZHelen Y. Zou
Helen Y. Zou
LFLuc Friboulet
Luc Friboulet
DKDavid P. Kodack
David P. Kodack
LELars D. Engstrom
Lars D. Engstrom
QLQiuhua Li
Qiuhua Li
TSTod Smeal
Tod Smeal

1 April 2021 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
GFGino B. Ferraro
Gino B. Ferraro
AAAhmed Ali
Ahmed Ali
ALAlba Luengo
Alba Luengo
DKDavid P. Kodack
David P. Kodack
ADAmy Deik
Amy Deik
MHMatthew G. Vander Heiden
Matthew G. Vander Heiden

24 May 2017 in Nature
Verified
Journal Article
Open access
PDF file
JKJiyeon Kim
Jiyeon Kim
ZHZeping Hu
Zeping Hu
LCLing Cai
Ling Cai
KLKailong Li
Kailong Li
ECEunhee Choi
Eunhee Choi
RDRalph J. DeBerardinis
Ralph J. DeBerardinis
In human cell lines with mutant KRAS and loss of LKB1, CPS1 expression correlates inversely with LKB1 expression; silencing CPS1 in these cells induces DNA damage and cell death as a result of pyrimidine depletion rather than ammonia toxicity. Cancer cells have an altered cellular metabolism to adjust to their metabolic needs for tumour cell proliferation. Ralph DeBerardinis and colleagues now show an unexpected role for the metabolic enzyme CPS1, which normally functions in the urea cycle. They show that, in lung cancer cells, CPS1 expression is increased when the tumour suppressor LKB1 is deleted, and functions to promote pyrimidine synthesis. This is important for supplying nucleotides for DNA synthesis during cancer cell proliferation. The authors suggest that CPS1-related pathways could represent therapeutic targets in lung adenocarcinomas. Metabolic reprogramming by oncogenic signals promotes cancer initiation and progression. The oncogene KRAS and tumour suppressor STK11, which encodes the kinase LKB1, regulate metabolism and are frequently mutated in non-small-cell lung cancer (NSCLC). Concurrent occurrence of oncogenic KRAS and loss of LKB1 (KL) in cells specifies aggressive oncological behaviour1,2. Here we show that human KL cells and tumours share metabolomic signatures of perturbed nitrogen handling. KL cells express the urea cycle enzyme carbamoyl phosphate synthetase-1 (CPS1), which produces carbamoyl phosphate in the mitochondria from ammonia and bicarbonate, initiating nitrogen disposal. Transcription of CPS1 is suppressed by LKB1 through AMPK, and CPS1 expression correlates inversely with LKB1 in human NSCLC. Silencing CPS1 in KL cells induces cell death and reduces tumour growth. Notably, cell death results from pyrimidine depletion rather than ammonia toxicity, as CPS1 enables an unconventional pathway of nitrogen flow from ammonia into pyrimidines. CPS1 loss reduces the pyrimidine to purine ratio, compromises S-phase progression and induces DNA-polymerase stalling and DNA damage. Exogenous pyrimidines reverse DNA damage and rescue growth. The data indicate that the KL oncological genotype imposes a metabolic vulnerability related to a dependence on a cross-compartmental pathway of pyrimidine metabolism in an aggressive subset of NSCLC.

1 November 2018 in Cell Metabolism
Verified
Journal Article
Closed access
KCKevin D. Courtney
Kevin D. Courtney
DBDivya Bezwada
Divya Bezwada
TMTomoyuki Mashimo
Tomoyuki Mashimo
KPKumar Pichumani
Kumar Pichumani
VVVamsidhara Vemireddy
Vamsidhara Vemireddy
EMElizabeth A. Maher
Elizabeth A. Maher

14 August 2024 in Nature
Verified
Journal Article
Open access
PDF file
DBDivya Bezwada
Divya Bezwada
LPLuigi Perelli
Luigi Perelli
NLNicholas P. Lesner
Nicholas P. Lesner
LCLing Cai
Ling Cai
BBBrooks Bailey
Brooks Bailey
RDRalph J. DeBerardinis
Ralph J. DeBerardinis
Most kidney cancers are metabolically dysfunctional1–4, but how this dysfunction affects cancer progression in humans is unknown. We infused 13C-labelled nutrients in over 80 patients with kidney cancer during surgical tumour resection. Labelling from [U-13C]glucose varies across subtypes, indicating that the kidney environment alone cannot account for all tumour metabolic reprogramming. Compared with the adjacent kidney, clear cell renal cell carcinomas (ccRCCs) display suppressed labelling of tricarboxylic acid (TCA) cycle intermediates in vivo and in ex vivo organotypic cultures, indicating that suppressed labelling is tissue intrinsic. [1,2-13C]acetate and [U-13C]glutamine infusions in patients, coupled with measurements of respiration in isolated human kidney and tumour mitochondria, reveal lower electron transport chain activity in ccRCCs that contributes to decreased oxidative and enhanced reductive TCA cycle labelling. However, ccRCC metastases unexpectedly have enhanced TCA cycle labelling compared with that of primary ccRCCs, indicating a divergent metabolic program during metastasis in patients. In mice, stimulating respiration or NADH recycling in kidney cancer cells is sufficient to promote metastasis, whereas inhibiting electron transport chain complex I decreases metastasis. These findings in humans and mice indicate that metabolic properties and liabilities evolve during kidney cancer progression, and that mitochondrial function is limiting for metastasis but not growth at the original site.

8 April 2021 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
DIEM TRANDIEM TRAN
DIEM TRAN
Rushendhiran KesavanRushendhiran Kesavan
Rushendhiran Kesavan
HRHalie Rion
Halie Rion
MSMona Hoseini Soflaee
Mona Hoseini Soflaee
ASAshley Solmonson
Ashley Solmonson
GHGerta Hoxhaj
Gerta Hoxhaj